Ian T. Meredith

Showing 1-20 of 24 articles

Interventions for valvular disease

Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system

Gooley R, Worthley S, Whitbourn R, Montarello J, Newcomb A, Allocco D, Meredith I

December 7, 2018 | 10.4244/EIJ-D-18-00664

Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Meredith I, Verheye S, Dubois C, Dens J, Farah B, Carrié D, Walsh S, Oldroyd K, Varenne O, El-Jack S, Moreno R, Christen T, Allocco D

April 20, 2018 | 10.4244/EIJ-D-17-00529

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy

Kereiakes D, Meredith I, Masotti M, Carrié D, Moreno R, Erglis A, Mehta S, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe R, Reitman A, Janssens L, Christen T, Dawkins K, Windecker S

March 20, 2017 | 10.4244/EIJ-D-16-00643

Coronary interventions

Intravascular ultrasound guidance improves clinical outcomes during implantation of both first- and second-generation drug-eluting stents: a meta-analysis

Nerlekar N, Cheshire C, Verma K, Ihdayhid A-R, McCormick L, Cameron J, Bennett M, Malaiapan Y, Meredith I, Brown A

January 20, 2017 | 10.4244/EIJ-D-16-00769

Interventions for valvular disease

Intrepid transcatheter mitral valve replacement system: technical and product description

Meredith I, Bapat V, Morriss J, McLean M, Prendergast B

September 18, 2016 | 10.4244/EIJV12SYA21

Coronary interventions

Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program

Abdel-Wahab M, Neumann F-J, Serruys P, Silber S, Leon M, Mauri L, Yeung A, Belardi J, Widimsky P, Meredith I, Saito S, Richardt G

July 20, 2016 | 10.4244/EIJY15M07_07

Interventions for valvular disease

The Accucinch transcatheter direct mitral valve annuloplasty system

Gooley R, Meredith I

September 17, 2015 | 10.4244/EIJV11SWA16

A Y-shaped bifurcation-dedicated stent for the treatment of de novo coronary bifurcation lesions: an IVUS analysis from the BRANCH trial

Sakata K, Koo B, Waseda K, Nakatani D, Yock P, Whitbourn R, Worthley S, Ormiston J, Webster M, Wilkins G, Honda Y, Meredith I, Fitzgerald P

March 20, 2015 | 10.4244/EIJY14M08_16

Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study

Sievert H, Schofer J, Ormiston J, Hoppe U, Meredith I, Walters D, Azizi M, Diaz-Cartelle J, Cohen-Mazor M

February 20, 2015 | 10.4244/EIJY14M12_01

Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study

Meredith I, Worthley S, Whitbourn R, Antonis P, Montarello J, Newcomb A, Lockwood S, Haratani N, Allocco D, Dawkins K

March 20, 2014 | 10.4244/EIJV9I11A216

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study

Buysschaert I, Dubois C, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger J, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky A, Bichalska M, Meis S, Verheye S

September 27, 2013 | 10.4244/EIJV9I5A93

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Meredith I, Verheye S, Weissman N, Barragan P, Scott D, Valdés Chávarri M, West N, Kelbæk H, Whitbourn R, Walters D, Kubica J, Thuesen L, Masotti M, Banning A, Sjogren I, Stables R, Allocco D, Dawkins K

July 26, 2013 | 10.4244/EIJV9I3A52

How should I treat a patient with symptomatic severe aortic stenosis and a 23 mm aortic annulus who is referred for transcatheter aortic valve replacement using the CoreValve prosthesis?

Ko B, Antonis P, Meredith I, Tchétché D, Eggebrecht H, Zierer A, Doss M

February 22, 2013 | 10.4244/EIJV8I10A186

Boston Scientific Lotus valve

Meredith I, Hood K, Haratani N, Allocco D, Dawkins K

September 30, 2012 | 10.4244/EIJV8SQA12

Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials

Kereiakes D, Popma J.J, Cannon L, Kandzari D, Kimmelstiel C, Meredith I, Teirstein P, Verheye S, Allocco D, Dawkins K, Stone G

June 27, 2012 | 10.4244/EIJV8I2A32

First-in-human experience with the Medtronic Bifurcation Stent System

Meredith I, Worthley S, Whitbourn R, Webster M, Fitzgerald P, Ormiston J

October 28, 2011 | 10.4244/EIJV7I6A108

PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses

Meredith I, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone G, Teirstein P, Starzyk R, Allocco D, Dawkins K

May 17, 2011 | 10.4244/EIJV7I1A15

Latest news

New issue

TAVR in sarcopaenia; CCTA or TEE in LAAC; Iintravascular lithotripsy, read the new issue

(CT scans of a sarcopaenic patient)

October 18, 2019

Free access

Medical device regulation in Europe – what is changing and how can I become more involved?

October 18, 2019

Free Access

New this week: Insights from an International CTO Registry

October 22, 2019

Free access

Guidelines, consensus & position papers

April 9, 2019

Editorial

When is it best to stop aspirin and who could ultimately benefit?

Aspirin-free antiplatelet regimens after PCI

October 9, 2019

Free access

The EuroIntervention health check 2019

October 4, 2019

Free Access

Last week's JAA: Hydrodynamic function with the ALLEGRA heart valve

October 15, 2019

Ian T. Meredith

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke